A New Mechanism Of How Do Cancer Cells Evade Immune Detection?🧬

In a fascinating study published in Nature, titled "Cancer cells impair monocyte-mediated T cell stimulation to evade immunity," led by Dr. Anna C. Obenauf and her team at the Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), they have uncovered a new mechanism that how cancer cells strategically manipulate the immune system to avoid destruction.
Paper Link: https://lnkd.in/eAptRfrz

🔎 The Gap in Understanding:
While CD8+ T cells need to be reactivated within the tumor microenvironment (TME) to mount an effective immune response, the exact cellular mechanisms enabling this reactivation were unclear. This study sought to identify these mechanisms and understand how cancer cells disrupt them.

📝 Key Discoveries:
The study reveals that inflammatory monocytes play a pivotal role in stimulating T cells within the tumor microenvironment (TME). In resistant tumors, these monocytes are either reduced or functionally impaired, preventing effective T cell activation. They identified that, in therapy-responsive tumors, specialized immune hubs form where T cells interact with monocytes, facilitating T cell proliferation and tumor control within the tumor.
They further demonstrate that monocytes stimulate T cells through a mechanism known as “cross-dressing”, where monocytes present tumor-derived antigens via MHCI complexes. Interestingly, they found that resistant cancer cells produce prostaglandin E2 (PGE2), which suppresses type I interferon (IFN-I) responses. This combination inhibits monocyte function and impairs T cell activation.
To counteract this, they used commonly prescribed non-steroidal anti-inflammatory drugs (NSAIDs), such as COX inhibitors, to block PGE2 production. They showed that targeting PGE2 synthesis and enhancing IFN-I responses successfully restores monocyte function, reactivates T cells, and resensitizes tumors to immune attack.

💡 Potential Translational Approaches:
The results of this paper offer that by targeting PGE2 with commonly used COX inhibitors (such as celecoxib or etoricoxib) and enhancing IFN-I responses, immune function can be restored, making tumors more responsive to immunotherapy. These findings suggest that combination therapies could overcome immune resistance, leading to more effective and personalized cancer treatments.

---------------------------------------
💠 مرکز تحقیقات ایمونولوژی سرطان و ایمونوتراپی دانشگاه علوم پزشکی اردبیل
💠 Cancer Immunology and Immunotherapy Research Center_ARUMS

🆔️ @CIIRC_ARUMS